|
|
|
| Clinical effect of Entecavir combined w ith Fuzheng Huayu Tablets in the treatment of liver cirrhosis com pensatory patients |
| CHEN Xing |
| First Department of Infection,Public Health Hospital of Yangjiang City,Guangdong Province,Yangjiang 529500,China |
|
|
|
|
Abstract ObjectiveTo investigate the clinical effect of Entecavir combined with Fuzheng Huayu Tablets in the treatment of decompensated hepatitis B patients.MethodsThe clinical data of 78 patients with decompensated hepatitis B from June 2015 to May 2016 in our hospital were retrospectively analyzed.The patients were divided into two groups(n=39)by random number table method.The patients in the control group were treated with Entecavir Dispersible Tablets.The patients in the treatment group were treated with Fuzheng Huayu Tablets on the basis of the control group.Both groups were treated for 1 year and were followed up for 3 months.The liver function indexes and serum liver fibrosis indexes were measured before and after treatment in both groups.The diameter of main portal vein and the spleen thickness before and after treatment were observed with abdominal ultrasonography.FibroScan was used to measure and record the liver cirrhosis(Stiffne value)before and after treatment.The negative rate of HBeAg and HBV DNA in both groups were calculated.The Child-Pugh scores and adverse reactions were compared between the two groups after treatment.ResultsThe indexes of ALT,AST,TBil,ALB and other indexes of serum liver fibrosis of HA,LN,PCⅢandⅣ-C in two groups after 1 year of treatment and 3 months of follow-up were significantly lower than those in the control group(P<0.05).After treatment,the above indexes in the treatment group were significantly better than those in the control group(P<0.05).The other two groups were significantly better than the treatment group before significantly reduced after treatment,the treatment group improved significantly better than the control group(P<0.05).The negative conversion rate of HBV DNA after treatment in treatment group was 89.74%,66.67%in control group,and Child-Pugh score was significantly lower than that in control group,the differences were statistically significant(P<0.05).But there was no statistical difference in the negative conversion rate of HBeAg between the two groups(P＞0.05).During the treament and after treatment of two groups,no serious adverse reactions occurred.ConclusionEntecavir combined with Fuzhenghuayu can significantly improve liver function in patients with decompensated hepatitis B and effectively inhibit or even reverse the progress of liver fibrosis.Compared with Entecavir alone,the clinical efficacy is better and the prognosis is more stable,which is worthy of clinical application.
|
|
|
|
|
|
| [1] |
黄社文.恩替卡韦治疗乙型肝炎肝硬化安全性研究[J].中国医药科学，2015，5（24）：51-53.
|
| [2] |
张立一，丁国锋.恩替卡韦联合和络舒肝胶囊治疗代偿期乙肝肝硬化的临床效果[J].中国当代医药，2017，24（3）：24-26.
|
| [3] |
中华医学会肝病学分会.慢性乙型肝炎防治指南（2015更新版）[J].传染病信息，2015，28（6）：321-325.
|
| [4] |
抗肝纤维化治疗.肝纤维化中西医结合诊疗指南[J].中华肝脏病杂志 2006，14（11）：866-870.
|
| [5] |
应灵军，陈华忠，张建伟，等.代偿期乙型肝炎肝硬化患者长期抗病毒治疗后临床特点和肝脏组织学改变[J].中华临床感染病杂志，2016，9（1）：13-18.
|
| [6] |
李学冬.扶正化瘀胶囊联合恩替卡韦治疗慢性乙型肝炎对患者肝纤维化、T淋巴细胞亚群、肾功能的影响及疗效评价[J].河北医药，2016，38（13）：2041.
|
| [7] |
谢宏晟，蔡丽敏，颜鸣鹤，等.恩替卡韦联合扶正化瘀胶囊治疗慢性乙型肝炎肝纤维化的效果观察[J].浙江医学，2016，38（8）：555-557.
|
| [8] |
李国焕，张均倡，胡萌，等.扶正化瘀胶囊联合恩替卡韦治疗乙型肝炎肝硬化疗效观察[J].中西医结合肝病杂志，2015，25（4）：217-219.
|
| [9] |
吕耀青.恩替卡韦联合扶正化瘀胶囊治疗失代偿期乙型肝炎肝硬化的临床效果[J].临床医学研究与实践，2017，2（7）：54-55.
|
| [10] |
陆利民.扶正化瘀胶囊联合恩替卡韦片治疗乙型肝炎肝硬化临床研究[J].新中医，2015，47（11）：60-61.
|
| [11] |
潘黎清，杜秀萍，陈建杰，等.扶正化瘀胶囊联合恩替卡韦治疗代偿期乙肝肝硬化临床观察[J].大家健康，2017，11（8）：113.
|
| [12] |
郭小平.恩替卡韦联合扶正化瘀治疗肝硬化代偿期78例疗效观察[J].中国医刊，2016，51（12）：96-98.
|
| [13] |
陈红艳，杨光辉.恩替卡韦联合扶正化瘀胶囊对慢性乙型肝炎肝纤维化治疗效果观察[J].徐州医学院学报，2015，35（5）：335-337.
|
| [14] |
郝瑞军.恩替卡韦联合扶正化瘀胶囊治疗乙型肝炎后肝硬化失代偿期疗效观察[J].中国药物与临床，2017，17（10）：1507-1509.
|
| [15] |
王贺，王千钧，孙风波，等.恩替卡韦联合扶正化瘀胶囊对代偿期慢性乙型肝炎肝硬化患者炎性因子及纤维化指标的影响[J].临床肝胆病杂志，2016，32（9）：1734-1738.
|
|
|
|
